Efficacy and safety of etanercept for postoperative pyoderma gangrenosum after infliximab serum sickness

Dermatol Ther. 2019 Jan;32(1):e12774. doi: 10.1111/dth.12774. Epub 2018 Nov 20.

Abstract

Non-peristomal postoperative pyoderma gangrenosum (PPG) is a rare subtype of pyoderma gangrenosum that occurs in the early postoperative period at surgical incisions, most commonly after breast surgery. Early diagnosis and treatment is essential to prevent severe scaring. TNF-alpha inhibitor infliximab was reported to be efficient in treatment of PPG refractory to systemic corticosteroids. However infliximab can be not well tolerated. We report the first case of etanercept efficacy in post-plastic breast surgery pyoderma gangrenosum after infliximab serum sickness.

Keywords: etanercept; postoperative pyoderma gangrenosum; serum sickness.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Dermatologic Agents / administration & dosage*
  • Dermatologic Agents / adverse effects*
  • Drug Substitution*
  • Etanercept / administration & dosage*
  • Female
  • Humans
  • Infliximab / adverse effects*
  • Mammaplasty / adverse effects*
  • Middle Aged
  • Pyoderma Gangrenosum / diagnosis
  • Pyoderma Gangrenosum / drug therapy*
  • Pyoderma Gangrenosum / etiology
  • Serum Sickness / chemically induced*
  • Serum Sickness / diagnosis
  • Treatment Outcome

Substances

  • Dermatologic Agents
  • Infliximab
  • Etanercept